Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

MALVERN, Pa., April 29, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that...

Related Keywords

Oregon ,United States ,University Of Arizona ,Arizona ,Phoenix ,Benjamin Bakall ,Linkedin ,Ocugen Inc ,Exchange Commission ,Clinical Research At Associated Retina Consultants ,Head Of Communications ,Oregon Health ,Nuclear Hormone Receptor ,College Of Medicine ,Science University Casey Eye Institute ,Foundation Fighting Blindness ,Clinical Research ,Associated Retina Consultants ,Clinical Assistant Professor ,Retinal Cell ,Gene Therapy Innovation Summit ,Science University Casey Eye ,Hormone Receptor Based Gene Modifier Therapy ,Hyatt Regency ,Private Securities Litigation Reform Act ,Markets ,